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S-1Abstract Background: Chemotherapeutic regimens for elderly patients with metastatic col-
orectal cancer (mCRC), such as bevacizumab combined with 5-ﬂuorouracil (5-FU) and leu-
covorin, often exclude oxaliplatin and irinotecan owing to the risk of toxicity. However,
treatment with infusional 5-ﬂuorouracil and leucovorin requires percutaneous port-catheter
placement and other precautions, causing unnecessary stress for patients as well as healthcare
workers.
Methods: We conducted a phase II study to evaluate the efﬁcacy and safety of bevacizumab
plus S-1 in elderly patients with previously untreated mCRC. Bevacizumab was given
intravenously every two weeks, and S-1 was administered orally on days 1–28 of a 42-day
cycle. The primary end-point was progression-free survival (PFS). The secondary end-points
were time to treatment failure, response rate (RR), overall survival (OS), treatment
completion status and safety.umachi,
936 M. Yoshida et al. / European Journal of Cancer 51 (2015) 935–941Results: From October 2007 through March 2010, 56 patients were enroled. The median PFS
was 9.9 months, the median OS was 25.0 months, and the RR was 57%. The main adverse
events of grade 3 or higher were hypertension (11%), diarrhoea (9%) and neutropenia (7%).
Conclusion: Our results suggest that combination chemotherapy with S-1 and bevacizumab
can be administered safely and continuously on an outpatient basis and is therapeutically
effective in elderly patients with mCRC.
 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CCBY
license (http://creativecommons.org/licenses/by/4.0/).1. Introduction
The recent introduction of molecularly targeted
chemotherapeutic agents has improved the outcomes
of patients with advanced and recurrent colorectal
cancer. Recent phase III clinical trials have reported a
median survival time of longer than 2 years [1,2].
Combination regimens such as FOLFOX or FOLFIRI
are similarly eﬀective in younger patients, but tend to
be associated with higher incidences of bone-marrow
toxicity in elderly patients with advanced or recurrent
colorectal cancer [3–8], requiring that these treatments
are used with caution in older patients.
Combination therapy with 5-ﬂuorouracil (5-FU) and
bevacizumab has been demonstrated to be safe and
eﬀective. In the AVF0780 g trial, a randomised phase
II study comparing 5-FU plus leucovorin (5-FU/LV)
with 5-FU/LV plus bevacizumab [9,10], the progres-
sion-free survival (PFS) was 9.0–9.2 months in the
5-FU/LV plus bevacizumab group despite the absence
of oxaliplatin, compared with 5.2–5.5 months in
the 5-FU/LV group. While no study has directly
compared FOLFOX plus bevacizumab with 5-FU/LV
plus bevacizumab, the results of previous clinical trials
[3,9,10] indicate that the median PFS is similar with
these regimens, and that 5-FU/LV plus bevacizumab is
better tolerated, with a lower incidence of adverse
events. These clinical results suggest that it may be unne-
cessary to use oxaliplatin or irinotecan in combination
with 5-FU as ﬁrst-line treatment and that sequential
chemotherapy based on 5-FU is useful.
In the phase III AVEX trial in elderly patients, beva-
cizumab and capecitabine were shown to be superior to
capecitabine alone with PFS as the primary end-point.
The main toxic eﬀect of capecitabine is known to be fre-
quent hand-foot syndrome [11].
S-1 (Taiho Pharmaceutical Co., Ltd., Tokyo, Japan)
is an anticancer preparation that is widely used in
Japan to treat advanced gastric, colon, pancreatic and
lung cancer. S-1 combines the 5-FU prodrug tegafur
(FT) with 5-chloro-2,4-dihydroxypyridine (CDHP) and
potassium oxonate [12]. Phase II studies of S-1 reported
a response rate (RR) of 40%, a median PFS of
5.4 months and high safety in Japanese patients with
unresectable or recurrent colorectal cancer [13,14].
The SOFT study showed S-1 and oxaliplatin plus
bevacizumab to be non-inferior to mFOLFOX6 plusbevacizumab, in terms of PFS, as ﬁrst-line treatment
for metastatic colorectal cancer (mCRC) [15]. To con-
ﬁrm and extend these results, we conducted a phase II
study of S-1 plus bevacizumab in elderly patients with
metastatic colorectal cancer.
2. Patients and methods
2.1. Patients
Patients with histologically conﬁrmed colorectal can-
cer and measurable metastatic disease were eligible for
enrolment in this study. Patients who had previously
received chemotherapy, radiotherapy, or both for meta-
static disease were excluded. Patients who had received
oral adjuvant ﬂuorouracil-based chemotherapy with
drugs other than S-1 were eligible, provided that they
had remained disease-free for at least 6 months after
the completion of such therapy.
Other eligibility criteria were as follows: age
P65 years; an Eastern Cooperative Oncology Group
(ECOG) performance status (PS) of 0, 1 or 2; treatment
with FOLFIRI or FOLFOX was not indicated; ability
to tolerate oral drug administration; electrocardiographic
results within normal limits; adequate baseline bone-mar-
row function (white cell count, >3500/mL to <12,000/
mL; neutrophil count, >1500/mL; haemoglobin concen-
tration, >9.0 g/dL; and platelet count, >100,000/mL);
adequate hepatic function (serum total bilirubin level,
<1.5 mg/dL; serum aspartate aminotransferase [AST]
and alanine aminotransferase [ALT] levels, <100 U/L);
adequate renal function (serum creatinine, <1.2 mg/dL;
creatinine clearance estimated by the Cockcroft–Gault
equation, >50 mL/min); a life expectancy of at least
90 days; and written informed consent from the patient.
The main exclusion criteria were as follows: surgical
procedures or open biopsy performed <28 days before
study entry; current use of anticoagulant or thrombolytic
therapy; severe drug allergy; treatment with aspirin
(>325 mg/day) or non-steroidal anti-inﬂammatory
drugs, except as required for cancer pain; treatment with
steroids; the concurrent presence of another cancer,
infection, serious pleural eﬀusion or ascites.
The study was approved by the institutional review
board of each participating centre and was registered
in the Clinical Trials Government Registry
(NCT00569699).
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Bevacizumab (5 mg/kg) was administered as a 90-,
60- or 30-min intravenous infusion every 2 weeks. The
infusion time was chosen based on whether the patient
showed any infusion-site reaction. S-1 was available in
capsule and granule preparations containing 20 or
25 mg of tegafur, respectively. Patients received S-1
orally twice daily (after breakfast and dinner) from the
evening of day 1 to the morning of day 29, followed
by a 14-day rest. The dose of S-1 was based on body sur-
face area (40 mg for <1.25 m2; 50 mg for 1.25–1.50 m2;
or 60 mg for >1.50 m2). This 6-week cycle was repeated
until onset of disease progression or a severe adverse
event. No patient received premedication with a 5-hy-
droxytryptamine-3-receptor antagonist. All treatments
were routinely given on an outpatient basis.
In patients with laboratory abnormalities, subsequent
treatment was withheld until the neutrophil and platelet
counts were >1500/mL and >75,000/mL, respectively;
the AST or ALT was <100 IU/L; the total bilirubin level
was <2.0 mg/dL; the serum creatinine level was
<1.2 mg/dL; and any diarrhoea, stomatitis or hand-foot
syndrome (HFS) had resolved to grade 0 or 1. The dose
of S-1 was reduced by one step if the neutrophil count
was less than 500/mL, the platelet count was less than
50,000/mL, the AST was 200 IU/L or higher, the ALT
was 200 IU/L or higher or the serum creatinine level
was 1.5 mg/dL or higher. In the event of grade 3 or
higher non-haematological toxicity (excluding con-
stipation, anorexia, fatigue and nausea), the dose of S-
1 was reduced by one step. The protocol treatment
was repeated until the onset of disease progression or
a severe adverse event. Treatment with bevacizumab
was withdrawn if patients developed bevacizumab-in-
duced uncontrolled hypertension, proteinuria, bleeding,
thrombosis, gastrointestinal perforation or hyper-
sensitivity of grade 3 or higher.2.3. Toxicity and response evaluation
Before enrolment, all patients underwent a physical
examination, complete blood cell count (CBC) with dif-
ferential counts, serum chemical analysis, electrocardio-
graphy, and computed tomography scanning or
magnetic resonance imaging, including documentation
of measurable disease. Toxicity was assessed according
to the Common Terminology Criteria for Adverse
Events, version 3.0 (CTCAE v3.0) [16].
During the study, all patients were evaluated weekly
for signs and symptoms of toxicity. CBC and diﬀerential
counts, liver function tests, measurements of blood urea
nitrogen, creatinine, and electrolyte levels, and urinalysis
were performed weekly. All toxic eﬀects were evaluated
weekly during the ﬁrst cycle, and then every 2 weeks
from the second cycle onward. Any serious adverseevents or deaths were reported by the investigators,
and the factors responsible were analysed. CT or MRI
scans were performed every 8 weeks to evaluate lesions.
Responses were evaluated according to the RECIST cri-
teria, version 1.0 [17]. Treatment response and safety
were assessed by the trial committee.2.4. Statistical methods
The primary end-point was PFS. The secondary end-
points were safety, RR, overall survival (OS), relative
dose intensity (RDI) and time to treatment failure
(TTF). We calculated the required sample size for this
study on the basis of a target PFS of 8.5 months and a
minimum PFS of 5 months, with a one-sided a error
of 0.05 and a b error of 0.2, and estimated that we
needed to enrol 50 patients. Therefore, the required sam-
ple size for analysis, to compensate for mid-trial exclu-
sions or ineligibility, was 55. OS was calculated as of
September 2012. TTF, PFS and OS were analysed by
the Kaplan–Meier method. RDI was calculated for each
drug on the basis of four treatment cycles.
The association of PS (0 versus 1), alkaline phos-
phatase activity (ALP) (<300 versus P300) and the
number of organs involved (1 versus P2) with PFS
and OS were evaluated by univariate and multivariate
analyses using a proportional hazards model as
described by Ko¨hne et al. [18].3. Results
3.1. Patient characteristics
Between October 2008 and March 2010, we enroled
56 patients with advanced colorectal carcinoma at eight
hospitals in Japan. This study was approved by the insti-
tutional review board of each hospital. All patients gave
written informed consent. The clinical characteristics of
the eligible patients are shown in Table 1. The median
age was 75 years (range, 66–85). The ECOG PS was 0
in 28 patients and 1 in 28 patients.
The median follow-up time was 34.6 months (range,
1.1–54.0 months). 56 patients received a total of 329
treatment courses (median, 5; range, 1–17). Thirty-ﬁve
patients (63%) received second-line chemotherapy based
on oxaliplatin (20 patients, 36%), irinotecan (10 patients,
18%), or combination therapy including bevacizumab
(13 patients, 23%). After second-line therapy, nine
patients (16%) received anti-epidermal growth factor
receptor antibodies. Three patients received surgery for
metastases after the completion of the study treatment.3.2. Eﬃcacy
Median PFS, the primary end-point of the study, was
9.9 months (95% conﬁdence interval [CI], 7.9–
Table 1
Patient baseline characteristics.
Variable Type No. (%) of patients (N = 56)
Age, years Median [range] 75 [66–85]
65–69 7 (12.5)
70–74 19 (33.9)
75–79 19 (33.9)
80– 11 (19.6)
Gender Male/Female 32 (57.1)/24 (42.9)
Eastern Cooperative Oncology Group performance status (ECOG PS) 0/1 28 (50.0)/28 (50.0)
Tumour site Colon/Rectum 34 (60.7)/22 (39.3)
Metastasis Liver 35 (62.5)
Lung 22 (39.3)
Lymph nodes 25 (44.6)
Peritoneal 15 (26.8)
No. of tumour sites 1/2 or more 23 (41.1)/33 (58.9)
One organ only Liver 9 (16.1)
Lung 8 (14.3)
Lymph nodes 6 (10.7)
Histopathological diagnosis Well diﬀerentiated 17 (30.4)
Moderately diﬀerentiated 34 (60.7)
Poorly diﬀerentiated 4 (7.1)
Others 1 (1.8)
Adjuvant chemotherapy Yes/No 10 (17.9)/46 (82.1)
0 
20
40
60
80
100
0 6 12 18 24 30 36 4842 54 (M)
(%)
Median OS: 25.0 months 
(95% CI: 19.4 31.6) 
Number at risk
56 55 48 36 28 20 6 3 3 1
Fig. 2. Overall survival.
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points were as follows: the median OS was 25.0 months
(range, 19.4–31.6 months) (Fig. 2) and the median TTF
was 7.5 months (95% CI, 5.9–9.1 months).
The response rate was 57% (95% CI, 43.2–70.3), with
a disease control rate (DCR) of 96%. The conﬁrmed
response rate was 43%, with an associated conﬁrmed
DCR of 89%. The response was evaluated according
to the protocol in all patients, but the conﬁrmed
response could not be evaluated in four patients (two
who refused to continue treatment and two who discon-
tinued treatment because of grade 1 or 2 gastrointestinal
toxicity after evaluation of the initial response).
All 56 patients had at least one measurable lesion.
The responses to treatment are shown in Table 2. One
patient had a complete response (CR), 31 had an uncon-
ﬁrmed partial response and 22 had stable disease. The
CR was achieved after 14 cycles of the protocol treat-
ment in a patient with liver metastasis.0
20
40
60
80
100
0 4 8 12 16 20 24 28 32 36
Median PFS: 9.9 months 
(95% CI: 7.9 11.1) 
(%)
(M)
Number at risk
56 51 33 17 10 3 2 1 0
Fig. 1. Progression-free survival.3.3. Toxicity
Toxicity was classiﬁed according to the worst grade
per patient across the 329 courses of treatment
(Table 3). The most common toxic eﬀects were neu-
tropenia, hypertension and diarrhoea, which were gener-
ally mild. With the exception of hypertension, the
incidence of grade 3 or 4 toxicity was less than 10%.
One patient had thalamic haemorrhage (not shown in
the table). There was no treatment-related death. The
treatment protocol was discontinued owing to toxicity
in 18 of the 56 patients.
3.4. Dose intensity
The median number of treatment cycles was ﬁve
(range, 1–17). The mean RDI for both S-1 and bevacizu-
mab was 80% (range, 8.9–100% and 33.3–100%,
respectively).
Table 2
Response rates.
No. (%) of patients (N = 56) CR PR SD PD NE RR (%) DCR (%)
Unconﬁrmed 1 (2) 31 (55) 22 (39) 2 (4) 0 (0) 57 96
Conﬁrmed* 1 (2) 23 (41) 26 (46) 2 (4) 4 (7) 43 89
Abbreviations: CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; NE, not evaluated; RR, response rate;
DCR, disease control rate.
* Not prespeciﬁed in the study protocol because the primary end-point in this study was progression-free survival.
Table 3
Adverse events (worst grades).
Event Grade Any grade (%) Grade P3 (%)
1 2 3 4
Neutropenia 1 12 4 0 30 7
Thrombocytopenia 20 3 1 1 45 4
Anaemia 14 24 1 0 70 2
Leukopenia 11 14 0 0 45 0
Diarrhoea 24 6 5 0 63 9
Fatigue 24 11 1 0 64 2
Anorexia 29 9 3 0 73 5
Hyperbilirubinemia 18 18 1 0 66 2
Stomatitis 20 5 0 0 45 0
Hyperpigmentation 24 1 0 0 45 0
Rash 12 3 1 0 29 2
Hypertension 9 5 6 0 36 11
Proteinuria 8 23 0 0 55 0
Epistaxis 16 0 0 0 29 0
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Fig. 3 shows the Kaplan–Meier curves of OS and
median OS according to risk group as deﬁned by
Ko¨hne’s index [18], based on PS (0 versus 1), ALP
(<300 versusP300) and the number of organs involved0 12 24 36 48
0 
20
40
60
80
(%)
100 Low risk
Intermediate risk
High risk
Risk group Median OS (months) 95% CI
HR
vs. low risk group p value
High (n=14) 14.4 7.5 - 25.0 4.21 <0.001
Intermediate (n=19) 28.5 18.5 - 32.3 1.63 0.237
Low (n=23) 35.3 22.3 - NR 1
Number at risk
14 10 4 0 0
Low risk
Intermediate risk
High risk
19 18 9 1 0
23 20 15 5 3
(M)
Fig. 3. Overall survival (OS) according to risk group.(1 versus P2), which have been reported to be predic-
tors of the response to ﬂuoropyrimidine therapy. PS
was 0 in 28 patients and one in 28. ALP was <300 in
32 patients and P300 in 24. The number of organs
involved was one in 23 patients and P2 in 33. Our
results showed that median OS according to Ko¨hne’s
index was longer in the low-risk group (35.3 months
[95% CI: 22.3–notreached]) than in the high-risk group
(14.4 months [95% CI: 7.5–25.0], hazard ratio 4.21
[95% CI: 1.83–9.91], P < 0.001; Fig. 3). Second-line
chemotherapy was given to 12 (86%) of the 14 patients
in the high-risk group, 10 (53%) of the 19 patients in
the intermediate-risk group and 13 (57%) of the 23
patients in the low-risk group.4. Discussion
We conducted a phase II study to evaluate the eﬃ-
cacy and safety of combination chemotherapy with bev-
acizumab plus S-1 in elderly patients with untreated
unresectable or recurrent colorectal cancer. Toxicity
was tolerable, and eﬃcacy outcomes in terms of RR
and PFS were comparable to those reported for
combination chemotherapy with 5-FU or capecitabine
in combination with bevacizumab in a phase 3 trial
[10,11].
This phase II trial may be considered as further con-
ﬁrmation that the S-1 compound can replace 5-FU or
capecitabine in combination with bevacizumab, with or
940 M. Yoshida et al. / European Journal of Cancer 51 (2015) 935–941without other drug combinations. Although as yet there
has been no phase III trial of S-1 plus bevacizumab alone,
the above conclusion is supported by the results of three
randomised phase III trials in Asia, comparing S-1 plus
oxaliplatin with capecitabine plus oxaliplatin [19],
FOLFIRI with S-1 plus irinotecan [20], and FOLFOX
plus bevacizumab with S-1/oxaliplatin plus bevacizumab
[15]. All these trials demonstrate the non-inferiority of S-
1 combination therapy compared with drug combina-
tions containing 5-FU or capecitabine, suggesting that
S-1 can replace 5-FU or capecitabine, at least in Asia.
The therapeutic usefulness of sequential chemother-
apy with molecularly targeted drugs has yet to be vali-
dated in well-designed clinical trials. However, the
FOCUS [21], CAIRO [22], and FFCD2000-05 [23] stud-
ies showed that OS does not diﬀer signiﬁcantly between
sequential chemotherapy (with ﬂuoropyrimidines alone
as ﬁrst-line therapy and oxaliplatin or irinotecan as sec-
ond-line therapy) and combination chemotherapy (with
ﬂuoropyrimidines and oxaliplatin or irinotecan as ﬁrst-
line therapy), suggesting the non-inferiority of sequen-
tial chemotherapy.
5-FU monotherapy may be particularly useful in
elderly or frail patients because of its low toxicity.
Many patients with colorectal cancer are elderly (aged
P65 years) and thus tend to have greater morbidity
and a higher risk of adverse reactions [24]. Poor tolera-
bility and severe adverse reactions may therefore pre-
clude aggressive chemotherapy. Our study group is
likely to have many subjects with reduced tolerance to
chemotherapy because the protocol required that
patients were 65 years or older.
The proportion of the elderly patients enroled in our
study who were frail is unclear because detailed data on
physical status were not collected. While the median OS
obtained in the studies on 5-FU/LV + bevacizumab
therapy (AVF2192g trial) and capecitabine + bevacizu-
mab therapy (AVEX trial) was 16.6 and 20.7 months,
respectively, our study achieved a considerably longer
median OS of 25.0 months. However, while 8% and
9% of patients included in the AVF2192g and AVEX
studies, respectively, had a PSP 2, this particular group
of patients was not included in our study [10,11]. It is
therefore likely that this diﬀerence in patient back-
ground is a contributing factor in our favourable OS.
The eligibility criteria required that treatment with
FOLFOX and FOLFIRI was not indicated. However,
our subjects included patients who did not want to
receive intensive chemotherapy, as well as those who
were ‘frail.’ Although treatment with FOLFOX and
FOLFIRI was not indicated in our subjects, 30 patients
subsequently received second-line chemotherapy with
oxaliplatin- or irinotecan-based regimens after the pro-
tocol treatment. The reasons for using these second-line
regimens are unfortunately not available for all patients.
However, it is possible that some patients who refusedFOLFOX or FOLFIRI as ﬁrst-line therapy consented
to second-line therapy with oxaliplatin- or irinotecan-
based regimens because their physical and mental condi-
tion had improved. Since PS and other data were not
collected at the initiation of second-line therapy, this
can only be a supposition; however, such diﬀerences in
patient status between the time of enrolment and the
start of second-line therapy may have allowed patients
to receive regimens including oxaliplatin or irinotecan.
Among patients’ demographic characteristics at
enrolment, PS, WBC, ALP, and the number of organs
involved, which are collectively known as Ko¨hne’s
index, have been reported to be predictors of the
response to ﬂuoropyrimidine therapy. Although none
of our subjects had a PS of two or higher, our results
are generally consistent with those reported by Ko¨hne
et al. regarding the prognostic factors for ﬂuoropyrim-
idine therapy, suggesting that these factors may apply
not only to 5-FU-based chemotherapy but also to other
therapies. However, it should be noted that the correla-
tion of OS with ALP and the number of organs involved
might be a reﬂection of tumour burden rather than a
direct eﬀect of treatment.
The fact that 86% of high-risk patients received sec-
ond-line chemotherapy suggests that such patients may
require intensive chemotherapy. The results of a risk-
stratiﬁed analysis based on the aforementioned prognos-
tic factors suggested that the outcomes of combination
therapy with ﬂuoropyrimidines and bevacizumab agree
with those of a previous study [18]. However, large
prospective clinical studies and additional analyses
may be necessary to verify this conclusion.
Combination chemotherapy with ﬂuoropyrimidine
and bevacizumab is currently positioned as one treat-
ment option for elderly patients with metastatic or unre-
sectable colorectal cancer, and new trials of this regimen
are being performed by the North Central Cancer
Treatment Group and Japanese Clinical Oncology
Group [25]. Standard chemotherapy for elderly patients
may change on the basis of the ﬁndings of these trials.
In conclusion, our results suggest that combination
therapy with S-1 plus bevacizumab can be administered
safely and continuously on an outpatient basis and may
be therapeutically eﬀective in elderly patients with
advanced or recurrent colorectal cancer.
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